Dr. Stuart K. Bisland Profile

Dr. Stuart K. Bisland

Scientific Associate at Princess Margaret Cancer Ctr

SPIE Involvement:

Author

Publications (20)

Proceedings Article | 3 December 2007 Paper

Pharmacology of photosensitizer in rats with metastatic breast cancer: time point determination for photodynamic therapy (PDT) treatment of vertebral metastases

Margarete Akens, Albert Yee, Lothar Lilge, Shane Burch, Cari Whyne, Brian Wilson, Stuart Bisland

Proceedings Volume 5969, 596917 (2007) https://doi.org/10.1117/12.628730

KEYWORDS: Spinal cord, Photodynamic therapy, Tissues, Breast cancer, Pharmacology, Bioluminescence, Surgery, Liver, Kidney, Radiotherapy

Read Abstract +

Proceedings Article | 27 February 2007 Paper

Two-photon photodynamic therapy and its potential application to age related macular degeneration

Aliaksandr Karotki, Mamta Khurana, Stuart Bisland, Eduardo Moriyama, E. Rand Simpson, Melanie Campbell, Hazel Collins, Harry Anderson, David Cramb, Brian Wilson

Proceedings Volume 6427, 64270R (2007) https://doi.org/10.1117/12.701086

KEYWORDS: Photodynamic therapy, Blood vessels, Luminescence, In vitro testing, Absorption, In vivo imaging, Aluminum, Tissues, Oxygen, Visualization

Read Abstract +

Proceedings Article | 27 February 2007 Paper

Hyperbaric oxygen therapy augments the photodynamic action of methylene blue against bacteria in vitro

S. Bisland, F. Dadani, C. Chien, B. Wilson

Proceedings Volume 6427, 64270F (2007) https://doi.org/10.1117/12.701046

KEYWORDS: Photodynamic therapy, Oxygen, Bioluminescence, Bacteria, Toxicity, In vitro testing, Proteins, Tissues, Control systems, Absorbance

Read Abstract +

Proceedings Article | 21 February 2007 Paper

Increased expression of mitochondrial benzodiazepine receptors following low-level light treatment facilitates enhanced protoporphyrin IX production in glioma-derived cells in vitro

S. Bisland, N. Hassanali, C. Johnson, B. Wilson

Proceedings Volume 6428, 64280B (2007) https://doi.org/10.1117/12.701488

KEYWORDS: Photodynamic therapy, Receptors, Control systems, Brain, In vitro testing, Proteins, Statistical analysis, Neurons, Confocal microscopy, Cancer

Read Abstract +

Proceedings Article | 6 March 2006 Paper

Photodynamic therapy for epilepsy

Edie Zusman, Manpreet Sidhu, Valerie Coon, Nicholas Scott, Stuart Bisland, Tara Tsukamoto

Proceedings Volume 6139, 61390W (2006) https://doi.org/10.1117/12.648288

KEYWORDS: Photodynamic therapy, Epilepsy, Brain, Luminescence, Electrodes, Electroencephalography, Tissues, Safety, Surgery, Animal model studies

Read Abstract +

Proceedings Article | 28 February 2006 Paper

To begin at the beginning: The science of bio-stimulation in cells and tissues

Stuart Bisland, Brian Wilson

Proceedings Volume 6140, 614002 (2006) https://doi.org/10.1117/12.647675

KEYWORDS: Tissues, Cell death, Calcium, Injuries, Laser therapeutics, Blood circulation, Spinal cord, Inflammation, Photodynamic therapy, Light emitting diodes

Read Abstract +

Proceedings Article | 13 October 2005 Paper

A rationale for treating leg length discrepancy using photodynamic therapy

Stuart Bisland, Crystal Johnson, Mohammed Diab, Brian Wilson

Proceedings Volume 5969, 596916 (2005) https://doi.org/10.1117/12.628156

KEYWORDS: Photodynamic therapy, Bone, Bioluminescence, Control systems, Biomedical optics, X-ray imaging, Ear, X-rays, Tissues, Oxygen

Read Abstract +

This study investigates the use of photodynamic therapy (PDT) in regulating bone development with a view to its potential role in treating Juvenile leg length discrepancy (LLD). Transgenic mice expressing the luciferase firefly gene upon activation of a promoter sequence specific to the vascular endothelial growth factor (VEGF) gene were subject to benzoporphyrin derivative monoacid (BPD-MA)-mediated PDT in the right, tibial epiphyseal growth plate at the age of 3 weeks. BPD-MA was administered intracardially (2mg/kg) followed 10 mins later by a laser light (690 +/- 5 nm) at a range of doses (5-27J, 50 mW output) delivered either as a single or repeat regimen (x2-3). Contra-lateral legs served as no-light controls. Further controls included animals that received light treatment in the absence of photosensitizer or no treatment. Mice were imaged for VEGF related bioluminescence (photons/sec/steradian) at t= 0, 24, 48, 72 h and 1-4 weeks post PDT. Faxitron^TM x-ray images provided accurate assessment of bone morphometry. Upon sacrifice, the tibia and femur of the treated and untreated limbs were harvested, imaged and measured again and prepared for histology. A number of animals were sacrificed at 24 h post PDT to allow immunohistochemical staining for CD31, VEGF and hypoxia-inducible factor (HIF-1 alpha) within the bone. PDT-treated (10 J, x2) mice displayed enhanced bioluminescence at the treatment site (and ear nick) for up to 4 weeks post treatment while control mice were bioluminescent at the ear-nick site only. Repeat regimens provided greater shortening of the limb than the corresponding single treatment. PDT-treated limbs were shorter by 3-4 mm on average as compared to the contra lateral and light only controls (10 J, x2). Immunohistochemistry confirmed the enhanced expression VEGF and CD31 at 4 weeks post-treatment although no increase in HIF-1α was evident at either 24 h or 4 weeks post PDT treatment. Results confirm the utility of PDT to provide localized effects on bone development that may be applicable to other related skeletal deformities.

Proceedings Article | 27 August 2005 Paper

Photodynamic therapy of diseased bone

Stuart Bisland, Albert Yee, Jeffery Siewerdsen, Brian Wilson, Shane Burch

Proceedings Volume 5863, 58630U (2005) https://doi.org/10.1117/12.633091

KEYWORDS: Photodynamic therapy, Bone, Tissues, Bioluminescence, Spine, In vivo imaging, Oxygen, Magnetic resonance imaging, Fluoroscopy, Cancer

Read Abstract +

Objective: Photodynamic therapy (PDT) defines the oxygen-dependent reaction that occurs upon light-mediated activation of a photosensitizing compound, culminating in the generation of cytotoxic, reactive oxygen species, predominantly, singlet oxygen. We are investigating PDT treatment of diseased bone. Methods: Using a rat model of human breast cancer (MT-1)-derived bone metastasis we confirmed the efficacy of benzoporphyrin-derivative monoacid (BPD-MA)-PDT for treating metastatic lesions within vertebrae or long bones. Results: Light administration (150 J) 15 mins after BPDMA (2.5 mg/Kg, i.v.) into the lumbar (L3) vertebra of rats resulted in complete ablation of the tumour and surrounding bone marrow 48 hrs post-PDT without paralysis. Porcine vertebrae provided a model comparable to that of human for light propagation (at 150 J/cm) and PDT response (BPD-MA; 6 mg/m², i.v.) in non-tumour vertebrae. Precise fibre placement was afforded by 3-D cone beam computed tomography. Average penetration depth of light was 0.16 ± 0.04 cm, however, the necrotic/non-necrotic interface extended 0.6 cm out from the treatment fiber with an average incident fluence rate of 4.3 mW/cm². Non-necrotic tissue damage was evident 2 cm out from the treatment fiber. Current studies involving BPD-MA-PDT treatment of primary osteosarcomas in the forelimbs of dogs are very promising. Magnetic resonance imaging 24 hr post treatment reveal well circumscribed margins of treatment that encompass the entire 3-4 cm lesion. Finally, we are also interested in using 5-aminolevulinic acid (ALA) mediated PDT to treat osteomyelitis. Response to therapy was monitored as changes in bioluminescence signal of staphylococcus aureus (SA)-derived biofilms grown onto 0.5 cm lengths of wire and subjected to ALA-PDT either in vitro or in vivo upon implant into the intramedullary space of rat tibia. Transcutaneous delivery of PDT (75 J/cm²) effectively eradicated SAbiofilms within bone. Conclusions: Results support the application of PDT to the treatment of primary or metastatic lesions within bone. Secondly, that ALA-PDT may be useful as a treatment for osteomyelitis. Further studies aim to optimize the parameters of delivering PDT into bone and explore imaging technologies that can be used for clinical PDT.

SPIE Journal Paper | 1 May 2005 Open Access

Photodynamic therapy for the treatment of metastatic lesions in bone: Studies in rat and porcine models

Shane Burch, Arjun Bogaards, Jeffrey Siewerdsen, Douglas Moseley, Albert Yee, J. Finkelstein, Robert Weersink, Brian Wilson, Stuart Bisland

JBO, Vol. 10, Issue 03, 034011, (May 2005) https://doi.org/10.1117/12.10.1117/1.1921887

KEYWORDS: Photodynamic therapy, Bone, Tumors, Spine, Spinal cord, Tissues, Tumor growth modeling, Breast cancer, Bioluminescence, Cancer

Read Abstract +

DOWNLOAD PAPER

Proceedings Article | 8 April 2005 Paper

Preclinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis

Stuart Bisland, Claudia Chien, Brian Wilson, Shane Burch

Proceedings Volume 5689, (2005) https://doi.org/10.1117/12.593352

KEYWORDS: Photodynamic therapy, Bioluminescence, In vitro testing, Bone, In vivo imaging, Control systems, Light sources, Optical fibers, Imaging systems, Tissues

Read Abstract +

Proceedings Article | 9 December 2004 Paper

Nicotinamide augments the survival and incidence of apoptosis in glioma cells following photodynamic therapy in vitro

Stuart Bisland, Nayan Modi, Brian Wilson

Proceedings Volume 5578, (2004) https://doi.org/10.1117/12.566180

KEYWORDS: Cell death, Photodynamic therapy, Tumors, Bioluminescence, Acquisition tracking and pointing, Brain, In vitro testing, Oxygen, Proteins, Luminescence

Read Abstract +

Proceedings Article | 14 June 2004 Paper

Photodynamic therapy for the treatment of metastatic lesions in bone: studies in rat and porcine models

S. Burch, Stuart Bisland, Jeff Siewerdsen, Arjen Bogaards, Douglas Moseley, A. Yee, J. Finkelstein, Brian Wilson

Proceedings Volume 5315, (2004) https://doi.org/10.1117/12.548174

KEYWORDS: Photodynamic therapy, Bone, Tumors, Spine, Spinal cord, Sensors, Breast cancer, Tissues, Control systems, Animal model studies

Read Abstract +

Proceedings Article | 15 December 2003 Paper

Metronomic photodynamic therapy (mPDT) -- headlights to lead the way forward: technical feasibility and rationale in brain tumor

Stuart Bisland, Lothar Lilge, Annie Lin, Arjen Bogaards, Brian Wilson

Proceedings Volume 5260, (2003) https://doi.org/10.1117/12.543443

KEYWORDS: Tumors, Brain, Light emitting diodes, Photodynamic therapy, Cell death, Tissues, Toxicity, Water, Light sources, In vitro testing

Read Abstract +

Proceedings Article | 15 December 2003 Paper

Photodynamic actinometry using microencapsulates: concepts and developmental approach

Stuart Bisland, James Austin, Brian Wilson, Lothar Lilge

Proceedings Volume 5260, (2003) https://doi.org/10.1117/12.543445

KEYWORDS: Oxygen, Luminescence, Photodynamic therapy, Advanced distributed simulations, Tissues, Sodium, Potassium, In vivo imaging, Medium wave, Optical spheres

Read Abstract +

This study describes the development of novel, fluorescent-based actinometer encapsulates as a means of discerning volumetric Photodynamic therapy (PDT) dosimetry relative to the incident light and reactive oxygen species (ROS) production. PDT relies on three main ingredients; oxygen, light and photo-activatable commpounds, although, the PDT response is definately contingent on the site and level of ROS generation. Providing a localized, in situ measurement of luminance and ROS generation is therefore critical when deciphering targetd photodynamci therapy (PDT) protocols in vivo. Toward this end, alginate-poly-L-lysine-alginate encapsulates were made using ionotropic gelation of sodium alginate droplets ranging from 75 to 200 μm in diameter. Two candidate dyes, ADS680WS (ADS) and R-phycoerythrin (RPE) were chosen based on photochemistry, chemical stabilty and sensitivity to changing pH and oxygen environments. Alginate beads were constructed with ADS conjugated to the inside and RPE attached to the outside layer. The production of ROS was initiated either chemically using increasing concentrations of potassium perchromate or photochemically using tetra-sulphonated aluminium phosphorescence (AlPcS₄). The generation of singlet oxygen was confirmed by the presence of a phosphorescence peak at 1270 nm. The resulting photodegradation and subsequent decrease in fluorescence of RPE was found to correlate very closely (p<0.001) with increasing perchromate or fluence respectively. This effect was independent of pH (6.5-8) and could be inhibited using sodium azide. RPA was not susceptible to photobleaching with light alone (675 nm; 150 J/cm²). Meanwhile, ADS680WS, which absorbs light at 670-690 nm, showed a direct correlation between diminished fluorescence (photobleaching) and incident fluence (675 nm; 0-100 J/cm²). This effect was independent of fluence rate (10-40 mW/cm²). We propose that actinometer encapsulates may prove useful for implanting into potential target areas such as the brain in order to determine the delivered dose of PDT at specific sites within that target area.

Proceedings Article | 16 October 2003 Paper

Metronomic photodynamic therapy (mPDT) for intracranial neoplasm: physiological, biological, and dosimetry considerations

Stuart Bisland, Lothar Lilge, Annie Lin, Brian Wilson

Proceedings Volume 5142, (2003) https://doi.org/10.1117/12.502111

KEYWORDS: Tumors, Brain, Photodynamic therapy, Light emitting diodes, Cell death, Light sources, Tissues, Toxicity, In vitro testing, In vivo imaging

Read Abstract +

Metronomic photodynamic therapy (mPDT), a procedure in which both the photosensitizer and light are delivered continuously so that the individual doses overlap pharmacologically is introduced. The fundamental hypothesis in mPDT is that by providing therapy at low fluence over extended periods of time, there is potential for improved selectivity in tumor cell kill through non necrotic pathways. This is especially important in the treatment of malignant brain tumors, in which selectivity between damage to tumor cells versus normal brain tissue is critical. Previous studies have shown that low-dose PDT using aminolevulinic acid (ALA)-induced protoporphyrin IX (PiIX) can induce apoptosis in tumor cells without causing necrosis in either tumor or normal brain tissue nor apoptosis in the latter. However, in order to achieve tumor control, multiple PDT treatments, such as hyper fractionation or metronomic delivery, are required, where the frequency and duration of the treatment are determined by the levels of apoptosis achieved in relationship to tumor cell doubling times, mPDT poses two substantial technical challenges: extended delivery of ALA and implantation of interstitial devices for extended light delivery at a sufficiently high enough density to achieve low fluence exposure to the brain adjacent to tumor or the entire hemisphere. In a rat model we evaluated the feasibility of delivering sustained ALA administration via the drinking water for up to 10 days without loss of PPIX selectivity. Post mortem quantitative spectrofluorimetry of tumor, normal brain and other tissues demonstrates a 4 times higher PPIX concentration in the 9L gliosarcoma model without noticeable toxicity. Light sources and delivery devices based either on laser diode or light emitting diode (LED) coupled to an implanted optical fiber were shown to be feasible. The maximum permissible spacing of cylindrical isotropic emitters is determined using known apoptotic indices and the necrosis threshold value for white matter. Preliminary evidence of selective apoptosis of tumor under these conditions is presented.

Proceedings Article | 23 July 2003 Paper

High-sensitivity detection and monitoring of microcirculation using cutaneous and catheter probes for Doppler optical coherence tomography

Victor Yang, M. Gordon, B. Qi, E. Seng Yue, S. Tang, Stuart Bisland, J. Pekar, S. Lo, Norman Marcon, B. Wilson, Alex Vitkin

Proceedings Volume 4965, (2003) https://doi.org/10.1117/12.503214

KEYWORDS: Photodynamic therapy, Skin, Doppler tomography, Blood circulation, Tumors, In vivo imaging, Optical coherence tomography, Esophagus, Endoscopy, Imaging systems

Read Abstract +

Proceedings Article | 13 June 2003 Paper

Metronomic photodynamic therapy (mPDT): concepts and technical feasibility in brain tumor

Brian Wilson, Stuart Bisland, Arjen Bogaards, Annie Lin, Eduardo Moriyama, Kai Zhang, Lothar Lilge

Proceedings Volume 4952, (2003) https://doi.org/10.1117/12.479435

KEYWORDS: Tumors, Brain, Photodynamic therapy, Light emitting diodes, Cell death, Tissues, Toxicity, Water, Light sources, Semiconductor lasers

Read Abstract +

Proceedings Article | 13 June 2003 Paper

Fluorescence-guided resection of intracranial VX2 tumor in a preclinical model using 5-aminolevulinic acid (ALA): preliminary results

Arjen Bogaards, Abhay Varma, Eduardo Moriyama, Annie Lin, Anoja Giles, Stuart Bisland, Lothar Lilge, G. Bilbao, Paul Muller, Brian Wilson

Proceedings Volume 4952, (2003) https://doi.org/10.1117/12.479426

KEYWORDS: Tumors, Luminescence, Tissues, Brain, Imaging systems, Imaging spectroscopy, Fluorescence spectroscopy, Microscopes, Tissue optics, Bioluminescence

Read Abstract +

Proceedings Article | 13 June 2003 Paper

Bioluminescence monitoring of photodynamic therapy response of rat gliosarcoma in vitro and in vivo

Eduardo Moriyama, Stuart Bisland, Annie Lin, Arjen Bogaards, Lothar Lilge, Brian Wilson

Proceedings Volume 4952, (2003) https://doi.org/10.1117/12.488634

KEYWORDS: Photodynamic therapy, Tumors, Bioluminescence, In vivo imaging, In vitro testing, Luminescence, Cell death, Cancer, Control systems, Brain

Read Abstract +

Proceedings Article | 6 June 2002 Paper

PDT-induced apoptosis: investigations using two malignant brain tumor models

Lothar Lilge, Keir Menzies, Stuart Bisland, Annie Lin, Brian Wilson

Proceedings Volume 4612, (2002) https://doi.org/10.1117/12.469343

KEYWORDS: Photodynamic therapy, Tumors, Brain, Cell death, Tissues, Tissue optics, Tumor growth modeling, Animal model studies, Natural surfaces, Image segmentation

Read Abstract +

Showing 5 of 20 publications

Conference Committee Involvement (3)

Mechanisms for Low-Light Therapy III

20 January 2008 | San Jose, California, United States

Mechanisms for Low-Light Therapy II

21 January 2007 | San Jose, California, United States

Mechanisms for Low-Light Therapy

22 January 2006 | San Jose, California, United States

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Keywords/Phrases

Search In:

Publication Years